Procedure:
In this cross-sectional study, 88 children aged 0 to 18 years old with
primary brain tumors were investigated. Data was extracted from
patients’ medical records. 38 patients received Irinotecan treatment
from the beginning (B) or after relapse (AB). At study termination, the
response rate to the treatment as well as the Overall Survival (OS) and
6 months Progression Free Survival (6-mo-PFS) were estimated using
Kaplan-Meier survival analysis and PFS estimation.